GALVmed makes livestock vaccines, medicines and diagnostics accessible and affordable to the millions in developing countries for whom livestock is a lifeline
About GALVmed
Peste des Petits Ruminants (PPR) is a highly contagious viral respiratory disease of goats and sheep causing up to 80 per cent mortality in flocks.
The total yearly cost of PPR is estimated to be US $874 million.
PPR and another viral disease, Sheep and Goat Pox (SGP), are often vaccinated separately and only during outbreaks. The vaccines are often controlled by governments and supplies can be limited.
A new combined vaccine against PPR and SGP is half the cost of previous options (only 20 US cents compared to 40 US cents) and only two doses a year are required.
Product development
GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world.
Policy and advocacy
The policy environment is a key determinant in the successful translation of research products to livestock health solutions that are sustainably available to smallholder farmers.
2018-04-19
2018-04-13
2018-04-09
GALVmed Chief Executive, Peter Jeffries, gives an insight into how GALVmed and its partners work to achieve its goal of making livestock vaccines, diagnostics and medicines accessible and affordable to millions of smallholder farmers.
GALVmed recently convened a meeting of key East Coast fever disease stakeholders in Uganda to discuss the final report of the ECF field safety and efficacy study. The meeting took place at the Lake Victoria …
Part 2: GALVmed CEO Peter Jeffries gives an update on the Brucellosis vaccine prize competition.
